speb/financial-data huggingface dataset:
Financial ratios for TMC — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 1.12
Shares outstanding: 433221138
Market cap (USD): 485207674.56000006
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for TMC — quarterly report dated 2025-03-31
Total revenue: 0
Operating income: -12597902.097902099
Net income: -14397202.797202798
Capital expenditures: 48951.04895104895
Operating cash flow: -6536363.636363637
Depreciation & amortization: 40559.44055944056
Net tangible assets: -13093706.293706294
Owner earnings: -14405594.405594405
Buffett classification: The Gruesome
Stock price: 1.72
Shares outstanding: 433221138
Book value: -11724475.524475522
Market cap (USD): 745140357.36
Debt to equity: -0.5951330072766314
Current ratio: 0.13324158412255763
Quick ratio: 0.13324158412255763
Interest coverage ratio: -17.64446620959843
Free cash flow (dilution-adjusted): -13842657.342657343
Buyback yield (%): 0
Retained earnings: -455960139.8601399
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -194.50442668969978
Rule of 40 score: 0
Financial ratios for TMC — quarterly report dated 2025-06-30
Total revenue: 0
Operating income: -16040145.985401459
Net income: -54263503.64963503
Capital expenditures: 36496.3503649635
Operating cash flow: -7782481.751824817
Depreciation & amortization: 42335.76642335766
Net tangible assets: 58263503.64963503
Owner earnings: -54257664.23357663
Return on net tangible assets (%): -93.12461632903621
Buffett classification: The Gruesome
Stock price: 6.6
Shares outstanding: 433221138
Book value: 59751824.81751824
P/B ratio: 47.852254212020526
Market cap (USD): 2859259510.7999997
Debt to equity: 0.030271194722697292
Current ratio: 2.3655727454263067
Quick ratio: 2.3655727454263067
Interest coverage ratio: -26.380552220888354
Free cash flow (dilution-adjusted): -14331386.861313868
Buyback yield (%): 0
Retained earnings: -530192700.72992694
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -17.705068604623055
Rule of 40 score: 0
Financial ratios for TMC — quarterly report dated 2025-09-30
Total revenue: 0
Operating income: -39826618.70503598
Net income: -132746043.16546763
Capital expenditures: 14388.489208633095
Operating cash flow: -8264028.776978418
Depreciation & amortization: 41007.19424460432
Net tangible assets: -30723741.007194247
Owner earnings: -132719424.46043167
Buffett classification: The Gruesome
Stock price: 6.37
Shares outstanding: 433221138
Book value: -29225899.28057553
Market cap (USD): 2759618649.06
Debt to equity: 0
Current ratio: 2.5027544091899054
Quick ratio: 2.5027544091899054
Interest coverage ratio: -81.29074889867842
Free cash flow (dilution-adjusted): -39188489.208633095
Buyback yield (%): 0
Retained earnings: -655310071.9424461
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -42.98693130197777
Rule of 40 score: 0
Financial ratios for TMC — quarterly report dated 2025-12-31
Total revenue: 0
Operating income: -32631386.861313865
Net income: -29487591.24087591
Capital expenditures: 76642.33576642335
Operating cash flow: -8288321.167883211
Depreciation & amortization: 57664.233576642335
Net tangible assets: -25962043.795620438
Owner earnings: -29506569.343065694
Buffett classification: The Gruesome
Stock price: 6.17
Shares outstanding: 433221138
Book value: -24410948.90510948
Market cap (USD): 2672974421.46
Debt to equity: 0
Current ratio: 2.031717705685281
Quick ratio: 2.031717705685281
Interest coverage ratio: -65.74264705882352
Free cash flow (dilution-adjusted): -33479562.043795615
Buyback yield (%): 0
Retained earnings: -694364233.5766423
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -36.573892270436545
Rule of 40 score: 0
Financial ratios for TMC — annual report dated 2025-12-31
Total revenue: 0
Operating income: -102229197.08029196
Net income: -233462773.72262773
Capital expenditures: 178832.11678832115
Operating cash flow: -31278102.18978102
Depreciation & amortization: 183941.60583941604
Net tangible assets: -25962043.795620438
Owner earnings: -233457664.23357666
Buffett classification: The Gruesome
Stock price: 6.17
Shares outstanding: 433221138
Book value: -24410948.90510948
Market cap (USD): 2672974421.46
Debt to equity: 0
Current ratio: 2.031717705685281
Quick ratio: 2.031717705685281
Interest coverage ratio: -43.56267496111975
Free cash flow (dilution-adjusted): -102020437.95620437
Buyback yield (%): 0
Retained earnings: -694364233.5766423
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -114.58046992604227
Rule of 40 score: 0
Financial ratios for TORNTPHARM.NS — annual report dated 2022-03-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 17.502044045892127
Shares outstanding: 380367856
Market cap (USD): 6657214969.353554
Buyback yield (%): 0
Retained earnings: 384634049.848345
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for TORNTPHARM.NS — annual report dated 2023-03-31
Total revenue: 1152702801.4616323
Gross profit: 808282582.2168088
Operating income: 260660170.52375153
Net income: 151672350.79171744
Capital expenditures: 50576126.67478685
Operating cash flow: 288444579.7807552
Depreciation & amortization: 85509135.20097443
Net tangible assets: 93917174.17783192
Owner earnings: 186605359.317905
Return on net tangible assets (%): 198.69141182268567
Capex to operating income (%): 19.403089690750555
Buffett classification: The Great
Stock price: 18.111327649208285
P/E ratio: 45.42005732279499
Shares outstanding: 380367856
Book value: 754941534.7137636
P/B ratio: 9.125166056540829
Market cap (USD): 6888966867.242875
Debt to equity: 0.8661664034126755
Current ratio: 0.9754777596240339
Quick ratio: 0.5661667247994419
Effective tax rate (%): 32.58678187054722
Interest coverage ratio: 6.441187093667229
COGS to revenue (%): 29.87935995367557
R&D to revenue (%): 0.33042079780719785
SG&A to revenue (%): 17.337317684750875
Free cash flow (dilution-adjusted): 218537149.817296
Buyback yield (%): 0
Retained earnings: 402337393.42265534
Inventory turnover: 1.2682271577474389
Receivables turnover: 4.868604088855964
Capitalized R&D asset: 3808769.792935445
ROCI (R&D-adjusted, %): 22.518832852915818
FCF margin (%): 18.958672568522424
Rule of 40 score: 18.958672568522424
Financial ratios for TORNTPHARM.NS — annual report dated 2024-03-31
Total revenue: 1266615901.1871927
Gross profit: 932315625.3747451
Operating income: 308472238.87756324
Net income: 198630531.23875764
Capital expenditures: 35870008.39429188
Operating cash flow: 391663268.97709554
Depreciation & amortization: 95371147.61961865
Net tangible assets: 232078186.8329536
Owner earnings: 258131670.4640844
Return on net tangible assets (%): 111.22616648581614
Capex to operating income (%): 11.628277644955002
Buffett classification: The Great
Stock price: 30.56142034548944
P/E ratio: 58.52364115743934
Shares outstanding: 380367856
Book value: 822178918.335532
P/B ratio: 14.138749697769065
Market cap (USD): 11624581933.128597
Debt to equity: 0.58661785404345
Current ratio: 1.034326528731395
Quick ratio: 0.6142408183954657
Effective tax rate (%): 29.578973772485128
Interest coverage ratio: 7.294756543686016
COGS to revenue (%): 26.393184824153053
R&D to revenue (%): 0.23413438916297666
SG&A to revenue (%): 18.00704580721452
Free cash flow (dilution-adjusted): 339764959.8273174
Buyback yield (%): 0
Retained earnings: 472766518.76723826
Inventory turnover: 1.2231875282461706
Receivables turnover: 5.727002114623434
Capitalized R&D asset: 5517459.1645525135
ROCI (R&D-adjusted, %): 26.631122672468276
Rosenberg metric: 32.56511942202294
FCF margin (%): 26.82462453762482
Revenue growth (%): 9.882261028698647
Rule of 40 score: 36.706885566323464
Financial ratios for TORNTPHARM.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 338150979.4553273
Buffett classification: The Gruesome
Stock price: 39.827161968466314
Shares outstanding: 380367856
Book value: 896321070.2341138
P/B ratio: 16.90127869531556
Market cap (USD): 15148972208.510271
Debt to equity: 0.41657782515991465
Current ratio: 1.2129152052816174
Quick ratio: 0.7443779657520114
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for TORNTPHARM.NS — annual report dated 2025-03-31
Total revenue: 1323036006.5466447
Gross profit: 985826513.9116203
Operating income: 342069207.3883563
Net income: 223433481.4122048
Capital expenditures: 69452887.53799392
Operating cash flow: 302210661.67874676
Depreciation & amortization: 92930792.61164367
Net tangible assets: 349375730.65232635
Owner earnings: 246911386.48585457
Return on net tangible assets (%): 70.67216318226839
Capex to operating income (%): 20.30375316979146
Buffett classification: The Great
Stock price: 37.26852608239001
P/E ratio: 63.44505430717615
Shares outstanding: 380367856
Book value: 887384849.1933599
P/B ratio: 15.974748019559541
Market cap (USD): 14175749362.238768
Debt to equity: 0.4218746912336032
Current ratio: 1.191932061248328
Quick ratio: 0.6532109158206475
Effective tax rate (%): 28.492859574754657
Interest coverage ratio: 11.63998727026812
COGS to revenue (%): 25.487552188031547
R&D to revenue (%): 0.2687932138991363
SG&A to revenue (%): 17.662329629547816
Free cash flow (dilution-adjusted): 230680383.4463409
Buyback yield (%): 0
Inventory turnover: 1.1350673880964093
Receivables turnover: 6.063516300999223
Capitalized R&D asset: 6800065.914909673
ROCI (R&D-adjusted, %): 28.33321099107194
Rosenberg metric: 18.04396682203808
FCF margin (%): 17.435684463981975
Revenue growth (%): 4.454397367549999
Rule of 40 score: 21.890081831531973
Financial ratios for TORNTPHARM.NS — quarterly report dated 2025-03-31
Total revenue: 340074818.798223
Gross profit: 254617722.70282906
Operating income: 89198036.00654663
Net income: 58218377.367313534
Capital expenditures: 0
Depreciation & amortization: 23497778.81692775
Net tangible assets: 349375730.65232635
Owner earnings: 81716156.18424128
Return on net tangible assets (%): 23.389190780844288
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 37.26852608239001
P/E ratio: 60.8731727131478
Shares outstanding: 380367856
Book value: 887384849.1933599
P/B ratio: 15.974748019559541
Market cap (USD): 14175749362.238768
Debt to equity: 0.4218746912336032
Current ratio: 1.191932061248328
Quick ratio: 0.6532109158206475
Effective tax rate (%): 25.112781954887218
Interest coverage ratio: 13.624999999999998
COGS to revenue (%): 25.1289102784462
Buyback yield (%): 0
Inventory turnover: 0.28765371372356124
Receivables turnover: 1.5585737630260654
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 7.427561803057663
Rule of 40 score: 0
Financial ratios for TORNTPHARM.NS — quarterly report dated 2025-06-30
Total revenue: 366019190.2644512
Gross profit: 275450503.1593728
Operating income: 97238474.13994852
Net income: 64123566.58085655
Capital expenditures: 0
Depreciation & amortization: 23519775.333489355
Owner earnings: 87643341.9143459
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 39.53054060379125
P/E ratio: 58.621766449255475
Shares outstanding: 380367856
Market cap (USD): 15036146975.985023
Effective tax rate (%): 25.745257452574528
Interest coverage ratio: 14.839285714285714
COGS to revenue (%): 24.744245524296677
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 7.629018684156614
Rule of 40 score: 7.629018684156614
Financial ratios for TORNTPHARM.NS — quarterly report dated 2025-09-30
Total revenue: 365952649.37993234
Gross profit: 275760992.10823
Operating income: 99098083.42728297
Net income: 66629086.809470125
Capital expenditures: 0
Depreciation & amortization: 22998872.604284104
Net tangible assets: 458399098.08342725
Owner earnings: 89627959.41375422
Return on net tangible assets (%): 19.552385636989673
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 40.26561443066516
P/E ratio: 81.04811287798695
Shares outstanding: 380367856
Book value: 952536640.3607666
P/B ratio: 16.078904246364775
Market cap (USD): 15315745431.514767
Debt to equity: 0.33400402414486924
Current ratio: 1.3914317925591881
Quick ratio: 0.8351747463359639
Effective tax rate (%): 25.28445006321112
Interest coverage ratio: 18.3125
COGS to revenue (%): 24.645717806531113
Buyback yield (%): 0
Inventory turnover: 0.3242805026347791
Receivables turnover: 1.48558352402746
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 7.933212996389892
Revenue growth (%): -0.01817961633945629
Rule of 40 score: -0.01817961633945629
Financial ratios for TORNTPHARM.NS — quarterly report dated 2025-12-31
Total revenue: 362147710.8165311
Gross profit: 273142475.2144369
Operating income: 98251086.10894509
Net income: 70736326.16687089
Capital expenditures: 0
Depreciation & amortization: 22947532.58326835
Owner earnings: 93683858.75013924
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 42.51086108945082
P/E ratio: 62.26148261948653
Shares outstanding: 380367856
Market cap (USD): 16169765089.308233
Effective tax rate (%): 21.990171990171994
Interest coverage ratio: 19.6
COGS to revenue (%): 24.577053214395573
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -1.0397352143366865
Rule of 40 score: -1.0397352143366865
Financial ratios for TRE.MC — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 7.238636363636363
Shares outstanding: 78093125
Market cap (USD): 565287734.375
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for TRE.MC — annual report dated 2022-12-31
Total revenue: 4503585106.382979
Gross profit: 928823404.2553192
Operating income: 7612765.957446809
Net income: -36685106.38297872
Capital expenditures: 2822340.425531915
Operating cash flow: 89351063.82978724
Depreciation & amortization: 27513829.787234046
Net tangible assets: 25312765.95744681
Owner earnings: -11993617.021276591
Return on net tangible assets (%): -47.38169286374714
Capex to operating income (%): 37.073784237003906
Buffett classification: The Good
Stock price: 8.893617021276595
Shares outstanding: 78093125
Book value: 88312765.95744705
P/B ratio: 7.864438829594985
Market cap (USD): 694530345.7446809
Debt to equity: 12.40190811188471
Current ratio: 1.1124074556108665
Quick ratio: 1.1103579014153842
Interest coverage ratio: 0.28372056141463803
COGS to revenue (%): 79.37591091730701
SG&A to revenue (%): 1.5103333750652552
Free cash flow (dilution-adjusted): 86412765.95744681
Buyback yield (%): 0
Retained earnings: 224765957.44680852
Inventory turnover: 434.14418604651166
Receivables turnover: 1.386998346428341
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 0.6881239007663019
FCF margin (%): 1.9187550344052136
Rule of 40 score: 1.9187550344052136
Financial ratios for TRE.MC — annual report dated 2023-12-31
Total revenue: 4594613333.333333
Gross profit: 1216524444.4444444
Operating income: 181185555.55555555
Net income: 67724444.44444445
Capital expenditures: 15522222.222222222
Operating cash flow: 92425555.55555555
Depreciation & amortization: 28822222.22222222
Net tangible assets: 298168888.8888889
Owner earnings: 81024444.44444445
Return on net tangible assets (%): 27.17401025518722
Capex to operating income (%): 8.567030729700061
Buffett classification: The Great
Stock price: 9.277777777777777
P/E ratio: 10.698214886303974
Shares outstanding: 78093125
Book value: 360574444.44444466
P/B ratio: 2.009378842248633
Market cap (USD): 724530659.7222221
Debt to equity: 2.793511587990766
Current ratio: 1.1413287377302366
Quick ratio: 1.1394302339057796
Effective tax rate (%): 42.1960283358495
Interest coverage ratio: 4.163802568751118
COGS to revenue (%): 73.5228112533711
SG&A to revenue (%): 1.9266280900919726
Free cash flow (dilution-adjusted): 76861111.1111111
Buyback yield (%): 0.001686915806559256
Retained earnings: 304392222.2222222
Inventory turnover: 465.1591187270502
Receivables turnover: 1.5779246722253872
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 15.409788660787516
FCF margin (%): 1.6728526545094353
Revenue growth (%): 2.0212391861172634
Rule of 40 score: 3.6940918406266987
Financial ratios for TRE.MC — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 13.166666666666666
Shares outstanding: 78093125
Market cap (USD): 1028226145.8333333
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for TRE.MC — annual report dated 2024-12-31
Total revenue: 4636922916.666667
Gross profit: 1273944791.6666667
Operating income: 193743750
Net income: 93689583.33333334
Capital expenditures: 7064583.333333334
Operating cash flow: 86528125
Depreciation & amortization: 34280208.333333336
Net tangible assets: 359428125
Owner earnings: 120905208.33333336
Return on net tangible assets (%): 33.63821579998319
Capex to operating income (%): 3.6463541834682847
Buffett classification: The Great
Stock price: 11.708333333333334
P/E ratio: 9.75925290742923
Shares outstanding: 78093125
Book value: 416286458.333333
P/B ratio: 2.19642104670512
Market cap (USD): 914340338.5416667
Debt to equity: 2.223621554668637
Current ratio: 1.1426210685429379
Quick ratio: 1.1407712874120073
Effective tax rate (%): 38.734541468260765
Interest coverage ratio: 4.659168336673346
COGS to revenue (%): 72.52607355003295
SG&A to revenue (%): 1.832977419022942
Free cash flow (dilution-adjusted): 78969791.66666667
Buyback yield (%): 0
Retained earnings: 378701041.6666667
Inventory turnover: 493.95027539779676
Receivables turnover: 1.6366976214559084
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 16.972671292629236
FCF margin (%): 1.703064577218279
Revenue growth (%): 0.9208518816237123
Rule of 40 score: 2.6239164588419914
Financial ratios for TRE.MC — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 11.708333333333334
Shares outstanding: 78093125
Market cap (USD): 914340338.5416667
Buyback yield (%): 0
Retained earnings: 378701041.6666667
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for TRE.MC — quarterly report dated 2025-03-31
Total revenue: 1424673913.0434783
Gross profit: 374565217.3913043
Operating income: 61304347.82608695
Net income: 30000000
Capital expenditures: 0
Depreciation & amortization: 9565217.391304348
Net tangible assets: 668913043.4782609
Owner earnings: 39565217.391304344
Return on net tangible assets (%): 5.914852128696782
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 17.380434782608695
P/E ratio: 11.310770550271739
Shares outstanding: 78093125
Book value: 680652173.913043
P/B ratio: 1.9941058268125216
Market cap (USD): 1357292466.0326087
Debt to equity: 1.014053018205047
Current ratio: 1.1482517870006097
Quick ratio: 1.146450933673187
Effective tax rate (%): 36.69724770642201
Interest coverage ratio: 7.726027397260275
COGS to revenue (%): 73.70870527199206
Buyback yield (%): 0
Inventory turnover: 148.63076923076923
Receivables turnover: 0.43091034618798696
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 5.011106175033319
Rule of 40 score: 0
Financial ratios for TRE.MC — quarterly report dated 2025-06-30
Total revenue: 1686328235.2941177
Gross profit: 407437647.0588235
Operating income: 75270588.23529412
Net income: 37027058.823529415
Capital expenditures: 0
Depreciation & amortization: 12311764.705882354
Net tangible assets: 499727058.8235294
Owner earnings: 49338823.52941177
Return on net tangible assets (%): 9.87315428657526
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 23.058823529411768
P/E ratio: 26.86580046688783
Shares outstanding: 78093125
Book value: 563812941.1764708
P/B ratio: 3.1938528840395537
Market cap (USD): 1800735588.2352943
Debt to equity: 2.014103551240398
Current ratio: 1.1675577006450677
Quick ratio: 1.16592447846713
Effective tax rate (%): 33.3961146146358
Interest coverage ratio: 4.312483149096792
COGS to revenue (%): 75.83876978803234
Buyback yield (%): 0
Retained earnings: 493143529.41176474
Inventory turnover: 166.31839045287637
Receivables turnover: 0.4167843802720333
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 5.069698448821244
Revenue growth (%): 18.365909549903737
Rule of 40 score: 18.365909549903737
Financial ratios for TRE.MC — quarterly report dated 2025-09-30
Total revenue: 2189436470.5882354
Gross profit: 456562352.9411765
Operating income: 98964705.88235295
Net income: 57678823.52941176
Capital expenditures: 0
Depreciation & amortization: 9688235.294117648
Net tangible assets: 614941176.4705882
Owner earnings: 67367058.8235294
Return on net tangible assets (%): 10.95504113258083
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 31.176470588235293
P/E ratio: 19.523281249999997
Shares outstanding: 78093125
Book value: 614941176.4705877
P/B ratio: 3.959188468528796
Market cap (USD): 2434668014.705882
Debt to equity: 1.837000191314331
Current ratio: 1.1223336015134053
Quick ratio: 1.1209202200526214
Effective tax rate (%): 33.01891958491909
COGS to revenue (%): 79.14703810435239
Buyback yield (%): 0
Inventory turnover: 226.6066153846154
Receivables turnover: 0.4825298174652562
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 7.281225655673854
Revenue growth (%): 29.834537829841235
Rule of 40 score: 29.834537829841235
Financial ratios for TRE.MC — annual report dated 2025-12-31
Total revenue: 7606889411.764706
Gross profit: 1725685882.3529413
Operating income: 348749411.7647059
Net income: 184396470.5882353
Capital expenditures: 18391764.70588235
Operating cash flow: 166595294.11764705
Depreciation & amortization: 45509411.76470588
Net tangible assets: 601910588.2352941
Owner earnings: 211514117.6470588
Return on net tangible assets (%): 35.14045470892687
Capex to operating income (%): 5.273633183442013
Buffett classification: The Great
Stock price: 32.51764705882353
P/E ratio: 13.771438620108844
Shares outstanding: 78093125
Book value: 663065882.3529406
P/B ratio: 3.8297923993002234
Market cap (USD): 2539404676.470588
Debt to equity: 1.603783494143073
Current ratio: 1.190273735035487
Quick ratio: 1.188805090462304
Effective tax rate (%): 34.36255523430255
Interest coverage ratio: 7.227526514689747
COGS to revenue (%): 77.31417154975306
SG&A to revenue (%): 1.44746496055588
Free cash flow (dilution-adjusted): 147736470.5882353
Buyback yield (%): 0.01987496861092698
Retained earnings: 610169411.7647059
Inventory turnover: 764.8444002447981
Receivables turnover: 1.7001505084788546
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 20.725033960623158
FCF margin (%): 1.9421403755357374
Revenue growth (%): 64.05037453659142
Rule of 40 score: 65.99251491212716
Financial ratios for TRE.MC — quarterly report dated 2025-12-31
Total revenue: 2189124705.882353
Gross profit: 456274117.64705884
Operating income: 108161176.47058824
Net income: 58631764.705882356
Capital expenditures: 0
Depreciation & amortization: 13156470.588235294
Net tangible assets: 601910588.2352941
Owner earnings: 71788235.29411764
Return on net tangible assets (%): 11.926727440464092
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 32.51764705882353
P/E ratio: 13.850972330062822
Shares outstanding: 78093125
Book value: 663065882.3529406
P/B ratio: 3.8297923993002234
Market cap (USD): 2539404676.470588
Debt to equity: 1.603783494143073
Current ratio: 1.190273735035487
Quick ratio: 1.188805090462304
Effective tax rate (%): 34.92735507976828
COGS to revenue (%): 79.15723501630521
Buyback yield (%): 0
Retained earnings: 610169411.7647059
Inventory turnover: 225.35541615667074
Receivables turnover: 0.4892724582104952
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 6.4276640474630735
Revenue growth (%): -0.014239495416772132
Rule of 40 score: -0.014239495416772132
Financial ratios for VIV — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 6.62
Shares outstanding: 1597803176
Market cap (USD): 10577457025.12
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for VIV — annual report dated 2022-12-31
Total revenue: 12833526893.939394
Gross profit: 3903310984.8484845
Operating income: 1208593939.3939393
Net income: 773676704.5454545
Capital expenditures: 1726537878.7878788
Operating cash flow: 3587485795.4545455
Depreciation & amortization: 2397703219.6969695
Net tangible assets: 3537592803.030303
Owner earnings: 1444842045.4545453
Return on net tangible assets (%): 40.84251992532587
Capex to operating income (%): 142.85508329238084
Buffett classification: The Gruesome
Stock price: 5.71
P/E ratio: 11.792336619880722
Shares outstanding: 1597803176
Book value: 12965122537.878786
P/B ratio: 0.7036922411111034
Market cap (USD): 9123456134.96
Debt to equity: 0.2819597864299305
Current ratio: 0.7795827108907604
Quick ratio: 0.7431055915189042
Effective tax rate (%): 16.013131078354935
Interest coverage ratio: 18.474037704386493
COGS to revenue (%): 40.482978547755664
SG&A to revenue (%): 17.74681910789362
Free cash flow (dilution-adjusted): 1713600189.3939393
Buyback yield (%): 1.2609916793092262
Inventory turnover: 33.91970561031946
Receivables turnover: 5.701512964856459
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 6.582079194157554
FCF margin (%): 13.352527357099186
Rule of 40 score: 13.352527357099186
Financial ratios for VIV — annual report dated 2023-12-31
Total revenue: 14686505773.195877
Gross profit: 4677268247.422681
Operating income: 1609453814.4329898
Net income: 1039170515.4639176
Capital expenditures: 1727195876.2886598
Operating cash flow: 3873386804.1237116
Depreciation & amortization: 2760736701.030928
Net tangible assets: 4248210309.278351
Owner earnings: 2072711340.206186
Return on net tangible assets (%): 48.79022433704042
Capex to operating income (%): 107.31565334772594
Buffett classification: The Gruesome
Stock price: 9.4
P/E ratio: 14.45321016223685
Shares outstanding: 1597803176
Book value: 14356148453.608246
P/B ratio: 1.046196332040929
Market cap (USD): 15019349854.4
Debt to equity: 0.2691073992220296
Current ratio: 0.9582147823381821
Quick ratio: 0.9146371592692041
Effective tax rate (%): 9.579243748919072
Interest coverage ratio: 13.934167566650897
COGS to revenue (%): 41.29662304633583
SG&A to revenue (%): 16.246169620073285
Free cash flow (dilution-adjusted): 2056614432.9896908
Buyback yield (%): 0.6709667617956326
Inventory turnover: 33.60911129874626
Receivables turnover: 5.93159898275312
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 7.755148151590826
FCF margin (%): 14.003429166542713
Revenue growth (%): 14.438578689787516
Rule of 40 score: 28.44200785633023
Financial ratios for VIV — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 9.2
Shares outstanding: 1597803176
Market cap (USD): 14699789219.199999
Buyback yield (%): 0
Retained earnings: 338292265.19337016
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for VIV — annual report dated 2024-12-31
Total revenue: 12422720711.974112
Gross profit: 3963250809.0614886
Operating income: 1443123462.7831717
Net income: 899244660.1941748
Capital expenditures: 1447820711.9741101
Operating cash flow: 3216273139.158576
Depreciation & amortization: 2298104368.932039
Net tangible assets: 3473775889.9676375
Owner earnings: 1749528317.1521034
Return on net tangible assets (%): 50.36387989808987
Capex to operating income (%): 100.3254918454364
Buffett classification: The Gruesome
Stock price: 6.87
P/E ratio: 12.206809008740452
Shares outstanding: 1597803176
Book value: 11294416666.666668
P/B ratio: 0.9718879817420111
Market cap (USD): 10976907819.12
Debt to equity: 0.2972303739446825
Current ratio: 0.9404890910146982
Quick ratio: 0.8924718212870433
Effective tax rate (%): 17.837242299420343
Interest coverage ratio: 15.450545624007109
COGS to revenue (%): 40.837791032596684
SG&A to revenue (%): 15.714658913812452
Free cash flow (dilution-adjusted): 1707515372.168285
Buyback yield (%): 4.069829421087682
Inventory turnover: 26.916344436813187
Receivables turnover: 6.0783935303920815
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 8.85802624310937
FCF margin (%): 13.745099900076085
Revenue growth (%): -15.414048080472387
Rule of 40 score: -1.6689481803963027
Financial ratios for VIV — quarterly report dated 2024-12-31
Capital expenditures: 437504207.11974114
Operating cash flow: 739461003.236246
Depreciation & amortization: 608597249.1909386
Buffett classification: The Gruesome
Stock price: 6.87
Shares outstanding: 1597803176
Market cap (USD): 10976907819.12
Free cash flow (dilution-adjusted): 301956796.11650485
Buyback yield (%): 0.48048941585379906
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for VIV — quarterly report dated 2025-03-31
Total revenue: 3439108159.7222223
Gross profit: 1103192881.9444444
Operating income: 376890972.2222222
Net income: 183717361.1111111
Capital expenditures: 411175694.4444445
Operating cash flow: 883826909.7222222
Depreciation & amortization: 644961111.1111112
Net tangible assets: 3490435937.5
Owner earnings: 417502777.77777785
Return on net tangible assets (%): 11.961336212828797
Capex to operating income (%): 109.09672153197857
Buffett classification: The Gruesome
Stock price: 8.19
P/E ratio: 17.807255574944907
Shares outstanding: 1597803176
Book value: 11830612152.777779
P/B ratio: 1.1061141927780516
Market cap (USD): 13086008011.439999
Debt to equity: 0.30170362239696963
Current ratio: 0.9641091385471221
Quick ratio: 0.9153753878956309
Effective tax rate (%): 25.392542574005667
Interest coverage ratio: 2.9071318666161363
COGS to revenue (%): 40.56628457101105
SG&A to revenue (%): 16.13536556105091
Free cash flow (dilution-adjusted): 463459895.8333334
Buyback yield (%): 0.4331373012678392
Retained earnings: 116255208.33333334
Inventory turnover: 6.1624389383517
Receivables turnover: 1.578394756634106
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.1742136984620988
FCF margin (%): 13.476165165761088
Rule of 40 score: 13.476165165761088
Financial ratios for VIV — quarterly report dated 2025-06-30
Total revenue: 2672462043.7956204
Gross profit: 1207794708.029197
Operating income: 448307299.27007294
Net income: 245338321.1678832
Capital expenditures: 395794525.54744524
Depreciation & amortization: 673167883.2116787
Net tangible assets: 3711691240.875912
Owner earnings: 522711678.83211666
Return on net tangible assets (%): 14.08284377417027
Capex to operating income (%): 88.28643347807895
Buffett classification: The Gruesome
Stock price: 10.82
P/E ratio: 40.293675339505924
Shares outstanding: 1597803176
Book value: 12434248540.145983
P/B ratio: 1.390371947971134
Market cap (USD): 17288230364.32
Debt to equity: 0.29814770782170663
Current ratio: 0.9825858367725695
Quick ratio: 0.9455833327954816
Effective tax rate (%): 13.950946671381272
COGS to revenue (%): 54.80591723152028
SG&A to revenue (%): 21.779651503725614
Free cash flow (dilution-adjusted): 662261496.3503649
Buyback yield (%): 0.5016144142400403
Retained earnings: 194244708.02919707
Inventory turnover: 8.092566098116494
Receivables turnover: 1.1970625601643787
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.4648203680001957
FCF margin (%): 24.78095050546627
Revenue growth (%): -22.292003633538645
Rule of 40 score: 2.4889468719276238
Financial ratios for VIV — quarterly report dated 2025-09-30
Total revenue: 3864470300.7518797
Gross profit: 1279115413.5338345
Operating income: 553405263.1578947
Net income: 354954699.2481203
Capital expenditures: 415656015.03759396
Operating cash flow: 866370676.6917293
Depreciation & amortization: 698921804.5112782
Net tangible assets: 3931417481.203007
Owner earnings: 638220488.7218045
Return on net tangible assets (%): 16.23385183011676
Capex to operating income (%): 75.10879326765657
Buffett classification: The Gruesome
Stock price: 12.14
P/E ratio: 24.74116544076547
Shares outstanding: 1597803176
Book value: 12876015789.473682
P/B ratio: 1.5064699262405052
Market cap (USD): 19397330556.64
Debt to equity: 0.26388993267835326
Current ratio: 1.0154681479772893
Quick ratio: 0.958049731077765
Effective tax rate (%): 10.229290570607825
Interest coverage ratio: 15.812682947789051
COGS to revenue (%): 39.61364429425542
SG&A to revenue (%): 15.517295554809085
Free cash flow (dilution-adjusted): 423517105.26315784
Buyback yield (%): 2.4694129255118344
Retained earnings: 403906015.03759396
Inventory turnover: 5.9398009068518585
Receivables turnover: 1.5830095548904943
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.9435265588065995
FCF margin (%): 10.959253721803929
Revenue growth (%): 44.603374619430866
Rule of 40 score: 55.5626283412348
Financial ratios for VIV — annual report dated 2025-12-31
Total revenue: 15030149817.518248
Gross profit: 4866721167.883211
Operating income: 1806073175.1824815
Net income: 1127288868.6131387
Capital expenditures: 1646170620.437956
Operating cash flow: 3780547810.218978
Depreciation & amortization: 2727081021.89781
Net tangible assets: 3787095802.919708
Owner earnings: 2208199270.0729923
Return on net tangible assets (%): 58.308513567852025
Capex to operating income (%): 91.14639667197486
Buffett classification: The Gruesome
Stock price: 11.29
P/E ratio: 16.002285092403113
Shares outstanding: 1597803176
Book value: 12591738321.167883
P/B ratio: 1.432621723619719
Market cap (USD): 18039197857.039997
Debt to equity: 0.29486778536836356
Current ratio: 0.9989759229398452
Quick ratio: 0.9381941727583224
Effective tax rate (%): 15.037939370450298
Interest coverage ratio: 12.483909621936345
COGS to revenue (%): 39.97484326546031
SG&A to revenue (%): 15.622615764000683
Free cash flow (dilution-adjusted): 2054716240.8759122
Buyback yield (%): 3.7369028524014727
Inventory turnover: 21.456670392080834
Receivables turnover: 6.028118923822098
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 9.625311939703396
FCF margin (%): 13.670630471567605
Revenue growth (%): 20.989195249562894
Rule of 40 score: 34.6598257211305
Financial ratios for VIV — quarterly report dated 2025-12-31
Total revenue: 3970382481.7518244
Gross profit: 1257597080.2919707
Operating income: 424370255.4744525
Net income: 345848175.1824817
Capital expenditures: 414671350.3649635
Operating cash flow: 938857481.7518247
Depreciation & amortization: 697482481.7518247
Net tangible assets: 3787095802.919708
Owner earnings: 628659306.5693429
Return on net tangible assets (%): 16.60003705437476
Capex to operating income (%): 97.71451816323801
Buffett classification: The Gruesome
Stock price: 11.29
P/E ratio: 15.965890376202681
Shares outstanding: 1597803176
Book value: 12591738321.167883
P/B ratio: 1.432621723619719
Market cap (USD): 18039197857.039997
Debt to equity: 0.29486778536836356
Current ratio: 0.9989759229398452
Quick ratio: 0.9381941727583224
Effective tax rate (%): 13.752630314327114
Interest coverage ratio: 11.640025226614078
COGS to revenue (%): 40.07293327381723
SG&A to revenue (%): 15.127782831417443
Free cash flow (dilution-adjusted): 494162773.7226277
Buyback yield (%): 0.34810751241470117
Inventory turnover: 5.681928048458623
Receivables turnover: 1.5923951566446761
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.2616448452928934
FCF margin (%): 12.446225923921357
Revenue growth (%): 2.740664897316928
Rule of 40 score: 15.186890821238286
Financial ratios for XBIO — annual report dated 2021-12-31
Capital expenditures: 0
Depreciation & amortization: 35482
Buffett classification: The Gruesome
Stock price: 12.9
Shares outstanding: 2291056
Market cap (USD): 29554622.400000002
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for XBIO — annual report dated 2022-12-31
Total revenue: 1706925
Operating income: -6717908
Net income: -6552353
Capital expenditures: 500000
Operating cash flow: -4646765
Depreciation & amortization: 27043
Net tangible assets: 13647134
Owner earnings: -7025310
Return on net tangible assets (%): -51.478281080848184
Buffett classification: The Gruesome
Stock price: 2.85
Shares outstanding: 2291056
Book value: 13647134
P/B ratio: 0.47845280921254235
Market cap (USD): 6529509.600000001
Debt to equity: 0
Current ratio: 12.722622806003974
Quick ratio: 12.722622806003974
COGS to revenue (%): 0
R&D to revenue (%): 279.4987477481436
SG&A to revenue (%): 214.06910086852088
Free cash flow (dilution-adjusted): -5658245
Buyback yield (%): 0
Retained earnings: -189099618
Capitalized R&D asset: 4770834
ROCI (R&D-adjusted, %): -19.205984069469554
FCF margin (%): -331.48761662053107
Rule of 40 score: -331.48761662053107
Financial ratios for XBIO — annual report dated 2023-12-31
Total revenue: 2539986
Operating income: -4515715
Net income: -4134578
Capital expenditures: 0
Operating cash flow: -4114219
Depreciation & amortization: 0
Net tangible assets: 9795641
Owner earnings: -4134578
Return on net tangible assets (%): -42.20834552838349
Buffett classification: The Gruesome
Stock price: 3.45
Shares outstanding: 2291056
Book value: 9795641
P/B ratio: 0.806904132154292
Market cap (USD): 7904143.2
Debt to equity: 0
Current ratio: 11.841713964562091
Quick ratio: 11.841713964562091
COGS to revenue (%): 0
R&D to revenue (%): 137.58993159804817
SG&A to revenue (%): 140.19510343757798
Free cash flow (dilution-adjusted): -4397304
Buyback yield (%): 0
Retained earnings: -193234196
Capitalized R&D asset: 6691223.78
ROCI (R&D-adjusted, %): -22.903988824166643
FCF margin (%): -173.12315894654537
Revenue growth (%): 48.804780526385166
Rule of 40 score: -124.3183784201602
Financial ratios for XBIO — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 4.32
Shares outstanding: 2291056
Market cap (USD): 9897361.92
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for XBIO — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 3.99
Shares outstanding: 2291056
Market cap (USD): 9141313.440000001
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for XBIO — annual report dated 2024-12-31
Total revenue: 2500284
Operating income: -4204428
Net income: -3960275
Capital expenditures: 0
Operating cash flow: -2817478
Net tangible assets: 6007180
Owner earnings: -3960275
Return on net tangible assets (%): -65.92569225493493
Buffett classification: The Gruesome
Stock price: 3.99
Shares outstanding: 2291056
Book value: 6007180
P/B ratio: 1.5217312349555032
Market cap (USD): 9141313.440000001
Debt to equity: 0
Current ratio: 7.366425760654304
Quick ratio: 7.366425760654304
COGS to revenue (%): 0
R&D to revenue (%): 131.5183395166309
SG&A to revenue (%): 136.63967773260956
Free cash flow (dilution-adjusted): -2989292
Buyback yield (%): 0
Retained earnings: -197194471
Capitalized R&D asset: 7204199.7700000005
ROCI (R&D-adjusted, %): -36.085605109611755
FCF margin (%): -119.55809820004448
Revenue growth (%): -1.5630794815404494
Rule of 40 score: -121.12117768158494
Financial ratios for XBIO — quarterly report dated 2025-03-31
Total revenue: 593261
Operating income: -942409
Net income: -903141
Capital expenditures: 0
Operating cash flow: -1001892
Net tangible assets: 5123290
Owner earnings: -903141
Return on net tangible assets (%): -17.62814519576288
Buffett classification: The Gruesome
Stock price: 2.61
Shares outstanding: 2291056
Book value: 5123290
P/B ratio: 1.1671516076583601
Market cap (USD): 5979656.16
Debt to equity: 0
Current ratio: 8.200441066164416
Quick ratio: 8.200441066164416
COGS to revenue (%): 0
R&D to revenue (%): 148.16901835785598
SG&A to revenue (%): 110.68332487724628
Free cash flow (dilution-adjusted): -1021143
Buyback yield (%): 0
Retained earnings: -198097612
Capitalized R&D asset: 879029
ROCI (R&D-adjusted, %): -5.937532921303694
FCF margin (%): -172.12373643303707
Rule of 40 score: -172.12373643303707
Financial ratios for XBIO — quarterly report dated 2025-06-30
Total revenue: 589897
Operating income: -724412
Net income: -688703
Capital expenditures: 0
Operating cash flow: -383830
Net tangible assets: 4450270
Owner earnings: -688703
Return on net tangible assets (%): -15.47553294519209
Buffett classification: The Gruesome
Stock price: 3.92
Shares outstanding: 2291056
Book value: 4450270
P/B ratio: 2.018066211712997
Market cap (USD): 8980939.52
Debt to equity: 0
Current ratio: 5.9259710215512
Quick ratio: 5.9259710215512
COGS to revenue (%): 0
R&D to revenue (%): 111.30027784511533
SG&A to revenue (%): 111.50285558326286
Free cash flow (dilution-adjusted): -399513
Buyback yield (%): 0
Retained earnings: -198786315
Capitalized R&D asset: 1245506.4300000002
ROCI (R&D-adjusted, %): -10.178015361463197
FCF margin (%): -67.72589113014645
Revenue growth (%): -0.5670354194865329
Rule of 40 score: -68.29292654963298
Financial ratios for XBIO — quarterly report dated 2025-09-30
Total revenue: 1026957
Operating income: -544734
Net income: -509940
Capital expenditures: 0
Operating cash flow: -658247
Net tangible assets: 3956185
Owner earnings: -509940
Return on net tangible assets (%): -12.889690446730878
Buffett classification: The Gruesome
Stock price: 3.14
Shares outstanding: 2291056
Book value: 3956185
P/B ratio: 1.818397228643251
Market cap (USD): 7193915.84
Debt to equity: 0
Current ratio: 4.558440331901688
Quick ratio: 4.558440331901688
COGS to revenue (%): 0
R&D to revenue (%): 73.66248051281602
SG&A to revenue (%): 79.38102569046221
Free cash flow (dilution-adjusted): -674102
Buyback yield (%): 0
Retained earnings: -199296255
Capitalized R&D asset: 1486454.76
ROCI (R&D-adjusted, %): -10.147183922139037
FCF margin (%): -65.64072302929918
Revenue growth (%): 74.09090061485311
Rule of 40 score: 8.45017758555393
Financial ratios for XBIO — annual report dated 2025-12-31
Total revenue: 2976411
Operating income: -2834582
Net income: -2680860
Capital expenditures: 0
Operating cash flow: -2286651
Net tangible assets: 7395822
Owner earnings: -2680860
Return on net tangible assets (%): -36.24830343401991
Buffett classification: The Gruesome
Stock price: 2.17
Shares outstanding: 2291056
Book value: 7395822
P/B ratio: 0.6722162215369705
Market cap (USD): 4971591.52
Debt to equity: 0
Current ratio: 8.315824488003926
Quick ratio: 8.315824488003926
COGS to revenue (%): 0
R&D to revenue (%): 102.99263105800914
SG&A to revenue (%): 92.24226761693866
Free cash flow (dilution-adjusted): -2351438
Buyback yield (%): 0
Retained earnings: -199875331
Capitalized R&D asset: 6421938.89
ROCI (R&D-adjusted, %): -22.08721338883534
FCF margin (%): -79.00246303349907
Revenue growth (%): 19.042916724660078
Rule of 40 score: -59.959546308838995
Financial ratios for XBIO — quarterly report dated 2025-12-31
Total revenue: 766296
Operating income: -623027
Net income: -579076
Capital expenditures: 0
Operating cash flow: -242682
Net tangible assets: 7395822
Owner earnings: -579076
Return on net tangible assets (%): -7.829771998298499
Buffett classification: The Gruesome
Stock price: 2.17
Shares outstanding: 2291056
Book value: 7395822
P/B ratio: 0.6722162215369705
Market cap (USD): 4971591.52
Debt to equity: 0
Current ratio: 8.315824488003926
Quick ratio: 8.315824488003926
COGS to revenue (%): 0
R&D to revenue (%): 100.92914487352145
SG&A to revenue (%): 80.37455500224456
Free cash flow (dilution-adjusted): -256680
Buyback yield (%): 0
Retained earnings: -199875331
Capitalized R&D asset: 1496922.75
ROCI (R&D-adjusted, %): -6.504508445869127
FCF margin (%): -33.49619468195058
Revenue growth (%): -25.38188064349335
Rule of 40 score: -58.87807532544393
Financial ratios for XL.V — annual report dated 2021-12-31
Capital expenditures: 3529.9212598425197
Buffett classification: The Gruesome
Stock price: 0.23622047244094488
Shares outstanding: 7252943
Market cap (USD): 1713293.622047244
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for XL.V — annual report dated 2022-12-31
Total revenue: 3264513.2352941176
Gross profit: 1485250.7352941176
Operating income: 1305660.294117647
Net income: -1091748.5294117646
Capital expenditures: 4711.029411764705
Operating cash flow: 1278923.5294117646
Depreciation & amortization: 194125
Net tangible assets: -24507570.588235293
Owner earnings: -902334.5588235293
Capex to operating income (%): 0.36081585945357825
Buffett classification: The Great
Stock price: 0.22794117647058823
Shares outstanding: 7252943
Book value: -24507570.588235293
Market cap (USD): 1653244.3602941176
Debt to equity: -1.131829222278734
Current ratio: 0.07167704039157859
Quick ratio: 0.07167704039157859
Interest coverage ratio: 0.4177777735951068
COGS to revenue (%): 54.50314860921973
SG&A to revenue (%): 5.501293094322232
Free cash flow (dilution-adjusted): 1274212.5
Buyback yield (%): 0
Retained earnings: -88616095.58823529
Receivables turnover: 4.878388015159057
Capitalized R&D asset: 0
FCF margin (%): 39.03223568597967
Rule of 40 score: 39.03223568597967
Financial ratios for XL.V — annual report dated 2023-12-31
Total revenue: 2494550.7575757573
Gross profit: 996900
Operating income: 762260.6060606061
Net income: -2823918.9393939395
Capital expenditures: 479.5454545454545
Operating cash flow: 147270.45454545453
Depreciation & amortization: 241400
Net tangible assets: -28285681.06060606
Owner earnings: -2582998.484848485
Capex to operating income (%): 0.06291095863182082
Buffett classification: The Great
Stock price: 0.1818181818181818
Shares outstanding: 7252943
Book value: -28285681.06060606
Market cap (USD): 1318716.909090909
Debt to equity: -1.0877016985170702
Current ratio: 0.041125865495929295
Quick ratio: 0.041125865495929295
Interest coverage ratio: 0.21153477838846282
COGS to revenue (%): 60.036892535760536
SG&A to revenue (%): 9.406078157632683
Free cash flow (dilution-adjusted): 147270.45454545453
Buyback yield (%): 0
Retained earnings: -94125350.75757575
Receivables turnover: 17.738932046157327
Capitalized R&D asset: 0
FCF margin (%): 5.903686429238033
Revenue growth (%): -23.585828030775012
Rule of 40 score: -17.68214160153698
Financial ratios for XL.V — quarterly report dated 2024-09-30
Capital expenditures: 23692.59259259259
Buffett classification: The Gruesome
Stock price: 0.15555555555555553
Shares outstanding: 7252943
Market cap (USD): 1128235.5777777776
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for XL.V — annual report dated 2024-12-31
Total revenue: 1425016.7832167833
Gross profit: -136927.97202797202
Operating income: -428674.12587412586
Net income: -4282545.454545455
Capital expenditures: 2587301.398601399
Operating cash flow: 711372.027972028
Depreciation & amortization: 665065.034965035
Net tangible assets: -29662843.356643356
Owner earnings: -6204781.818181818
Buffett classification: The Gruesome
Stock price: 0.15384615384615385
Shares outstanding: 7252943
Book value: -29662843.356643356
Market cap (USD): 1115837.3846153847
Debt to equity: -1.1405643320199088
Current ratio: 0.03675959182420422
Quick ratio: 0.03675959182420422
Interest coverage ratio: -0.11330609691877816
COGS to revenue (%): 109.6088673228729
SG&A to revenue (%): 20.473173178183647
Free cash flow (dilution-adjusted): -1875929.3706293707
Buyback yield (%): 0
Retained earnings: -91167484.61538462
Receivables turnover: 2.6280192364486594
Capitalized R&D asset: 0
FCF margin (%): -131.64261591324652
Revenue growth (%): -42.87481307449376
Rule of 40 score: -174.5174289877403
Financial ratios for XL.V — quarterly report dated 2024-12-31
Capital expenditures: 2618227.272727273
Buffett classification: The Gruesome
Stock price: 0.15384615384615385
Shares outstanding: 7252943
Market cap (USD): 1115837.3846153847
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for XL.V — quarterly report dated 2025-03-31
Total revenue: 1054311.1888111888
Gross profit: 322810.4895104895
Operating income: 267216.0839160839
Net income: -784520.979020979
Capital expenditures: 96841.25874125875
Operating cash flow: 743266.4335664336
Depreciation & amortization: 160839.16083916085
Net tangible assets: -30454776.923076924
Owner earnings: -720523.0769230769
Capex to operating income (%): 36.24080456611684
Buffett classification: The Good
Stock price: 0.18181818181818182
Shares outstanding: 7252943
Book value: -30454776.92307692
Market cap (USD): 1318716.9090909092
Debt to equity: -1.1213354038572063
Current ratio: 0.023832575820588283
Quick ratio: 0.023832575820588283
Interest coverage ratio: 0.25385716145867937
COGS to revenue (%): 69.38185870203262
SG&A to revenue (%): 5.273054690531385
Free cash flow (dilution-adjusted): 646425.1748251749
Buyback yield (%): 0
Retained earnings: -91952005.59440559
Receivables turnover: 4.116345358390009
Capitalized R&D asset: 0
FCF margin (%): 61.3125594876846
Rule of 40 score: 61.3125594876846